# A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

> **NCT05259709** · PHASE1 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** 89Zr˗DFO˗REGN5054
- **DRUG:** cemiplimab

## Key facts

- **NCT ID:** NCT05259709
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-07
- **Primary completion:** 2027-01-06
- **Final completion:** 2027-01-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259709, "A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05259709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*